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Thmmbolysis with a variay ofagents in patients with acute 
myocardial infmzlion has been shown to have a beneficial 
c&t an in-hospital and I-year survival (I-7). Although not 
consistentlv shown, benefit is tbcqbt to be mediated, at 
least in pd. by a nxluction in infarct size and an improve- 
ment in ejection fraction. The Sect of tbmmbdytic therapy 
on lag-term (3 to 8 years) survival is less clearly dncu- 
mated (8.9). For patients with wtc myardial infarction, 
admission clinical characteristics (ape, infarct bcation, the 
b4ltvl md infarct size and election fraction have hsen 
long-term 3mvival (10-13). The mle of admi&m clinical 
variables, randomiaii to rhmmbolytic treatment and 
mwwremerds of infarct size and ejection fraction in ri%- 
stratifying patients 6x lon9-tcrm survival after acute my+ 
caniial infarction has not been fully asaeassd in a larlp 
randomized study. 
The purpose of our study vms to obtain S to &yew 
follow-up data on 618 patients enmllcd in the sodomized. 
ccbocontmlkd Westcrn Washington Intmcoronary and 
trwenous Streplokinau trials between 1981 and 1986 and 
4enine the long-term effects on survival of receiving 
~tokinse treatment (1.14-16). In a subset af patients. 
: also evaluated the predictive role on survival if admia- 
an clinical characteristics. randomizatinn to streptokinase 
erapy and late radionuclide measurements of ejection 
action and tomogmptdc thallium->I infarct size on sur- 
valat3toSyears. 
MethOd. 
Study ptlmk?. The specific details and results of the 
restm~ Washington strepakinase trials have been previ- 
lsly published (I. 14-16). tktween luly 16. IYSI and land- 
y 30. 1983. a cotal of 250 &ems were enrolled in the 
mdomized. plaeeboeotttrolkd Westem Washington lntra- 
xonw Sttetiittasetrtaitl.l4l. Patients GS uearssdzc 
ith typical eiectmcardic$raphic (ECG) signs of Lee tt& 
wml myaardial ittfat’ctiott and Symplottts of <I? h duta- 
on underwent emeqency cardiac catheterization and those 
rho had M aceluded or pmtially oc&ded infalrt-related 
rtmy were enrolled in the study and randomized to receive 
drwuwmw streptuhinax UT routine coxruy cum. Gne 
tmdred thirty-four patients received 4,tMO U/min d intra- 
onnary stfeptokittase to a maximum of350,WO U (2&.ooO 
:~.S00U)~amanof4.6haflerlymptomonK1,8nd116 
atimts received eowentional care. At Ildays. there wasa 
iftnificard morillity reduction in patients rceeiving strep 
>ldnaPe (3.7% vs. 11.296. p 4 0.02). Tomographic thallium 
01 itt&t size and I& ventricular ejection fraction. ma+ 
wed at a core labcmtory 9 * 5 weeks after enmllmettt. 
vensimflarintketwogtwps. 
StattinS Septemar I. 1983, and cndix July 31.1996. the 
Hestem waskkwm fnlravntws &-ant* trial ran- 
lomized 369 pat&a to recsivc eith& t .5 million U d 
nlmenous strentokinase over I h or convendonal thempv 
tot ittclttditk9 thmmbdytic agents (15.16). Patients s?S 
wars Op ay with typical ECG signs of acute ttatwmtml 
nyoxtdial lnfanztion and symptoms of<6 h duration were 
mmlkd. Thcrc were 191 pimts treated with sttwt&it~asc 
L mean of35 h &I the onset of symptoms and l7+ patients 
uho received convmtional treatment. Mortality at I4 days 
was lower in the treatment group (6.3% VI. 9.6%). but this 
wetwIce ws w signitlat (p = 0.23). Rmliilide 
issessmettt war perfomted 8 + 7.5 weeks after mmllment 
ad showed dmt patients receiving shqtokinase bad a 
d&u ejection fraction tbatt that of the contml gmup (51 2 
IS vs. 47 * 15, p = 0.08) and a signi6eantly smatlet iofam 
tize (15 + 13% “I. I9 * 13%. p = 0.03). 
In both ntudies. the followi~ clinical variables were 
recorded for each patient on entry: a~eBe, gender. infarct 
lxatkm, hiatwy dpriormyocafdial infarction, the presence 
need fm ekflricsl the dun& of &I 
pain symptoms. Althou& cardiac catheterization was rec. 
amended in all patients in the intraven~nx smdy. manage 
ment after enmllment was detamined by the patient’s 
i.+t~t,‘~~~! physician and lm@en m&al thew was not 
c~rdied. 
Folbwup. Appiowd for contatmg patients or relatives 
to obtain follow-up war fxotidcd by the University of 
Washington Human Subjects Committee. We determined 
survival status at a minimum oi 3 years by using a mailed 
questionnaire a tekphorr eontaet with the patient. smviv- 
ittg relatives 0T the patienrs physician. For 22 fatients who 
could not he contacted, we reviewed the Naiml Death 
Index (17) and identified 2 additional deaths. Thus, we were 
able to determine survival status at a minimum of 3 years 
fmean4.9= 2.3)ia97%&bc&&ntsenmlled~Tbemlmb-er 
of patients with eonmary artery bypass Baftipg or percua- 
Pecus transluminal eormuy at@qdasty proeedwes was 
ascertained by qu4otiotmaire or tekphwe interview. 0T 
both, at I year and at the time of last FoSowup. 
St&tkalat~alys& Dataarepresmttaiertbemeanvalw 
* I SD. DitTerence5 in survival relative to tnatmmt. infarcl 
size and ejection fraction mm determined Imm survival 
eu~yes obtained with the &UU lindt method. Ste~wire 
Cox regression analysis & pufcamed to identify cbe cIio- 
ical and radionuclide wiables that were predictive of Ioqg- 
term survival. The survival analysis used data from the 
mtb’e period of follow-up (ma*mum 8 years). A p vale 
< 0.05 was wmsidered simdtk~t. Discrete variables were 
Clinical Chamcferistics an Eniy (Table I) 
00 entry into the study. the 325 patients receiving slrep 
cDkinareitndthe293eonnolptient~wererompared~agc, 
Sender, infarct !ocation, history of prior int?netion. a&- 
L w.n 01 Fdlow.up =o 3 I ‘ I 
genie shock. pulmonary edema and the need far electrical 
d&rillatbn. The two groups were well matched for most 
wiables. Mints receiving sbqtokinsse had a higher 
incidence of pulmonary edema 
Survival 
All patients. Fii I shows the cumdaiivc survival mtcs 
for the streptokinoge and control groups. The sutival rate at 
6 weeks wa* higher in stmptokinw~trested patients (19 
deaths 194% su’vivrdl vs. 34 deaths IB% sutvivdl in the 
contmlgroUp, chi-sq& p = 0.01). tiri~ the twtt&der 19 
the survival mte remained higher in the 
streptokiase group than in the contml gmup (84% vs. 82% 
at 3 years and 66% vs. 76% at 5 years). However. despite 
impmved early survival and an overall uend for better 
survival in stre#okinf~~~treatcd 9atients. for the en& 
follow-uo ariod this ditlarae between mams was not 
s@tilkai ip = 0.16). 
_ . 
Rlitnt5wiulmllolior~iFi~2showsthe 
cumtbtive stnvival rate for patients with atttaior tttyr~ 
cardial infarction. The survival rate at 6 weeks was sig- 
ni6cantly biir for natients wxivinza stratc&inak (13 
deaths ~306ayvivd]~vs. 27 deaths 17896 s&ivdl in & 
control group. p = O.OD7). The survival rate at 3 yars wan 
7646 for the StrEptokina~ Boup “as 67% for the control 
~mupand~5ycarsilw~68Rofortbestreptol;inaregmup 
vs. 62% in the canml grwp. These survival dit?ereoces 
were not signiticant over the entire follow-up period (p = 
0.14). 
far&m and the= ww ; &&ib 
CUM trend for impmcd survival in 
mtients rcceivilu strcntokinasc 
Menk with bderior LIMi4. Pi- 3 shows the eu- 
mtdatiw sorvivol rdte for patimb wifh inferior oryccordial 
iofamioo. TIE sorvIvo1 rate is similar in the ruepkkinase 
gmep and IIE comml #mup ond bigher than the rote in 
patients in the ccaaol sod tread sobgnxps of pat*ms with 
mkrior infarctien. The survival rok at 3 years was 69% for 
themcptoirinase ~mup versus91%forthe cmmvlgrcup snd 
of 5 years it was 88% in Ibe strepkkiease group end lU% b 
Ihe umtrolgwp. Over the ~lfolbw.u~ period. there w 




dysis was used to s&cl predictors ef survival in 594 
patients wlm had com&k admission data. Ankrim my* 
cadill iofawia, advanced age, history dprior myocardial 
-,andtbepreacaccofpulamnaryedern 
tea&m mre associakd wi$ d~reascd survival (Table 2). 
Ahhot@ there waa an sMonatlon between receiving strep 
tokinose end improved so&al. this result wu oc4 skdsti- 
cay sgieoot l.p - Cl.CE.9). 
lklolknof~~karvival Pii4sbows 
the cumolnrive survival rote of412 p&ok who bed ejection 
Rxdoo measured by mdkmoc6i kdmiqoes at 8.4 2 6.0 
weeks ah enmOment. hticnlo were stratified. without 
(18). for each of the th& ej.&o t&i& pm;p;. there 
we a similar number of slreptokinowreokd and umtml 
paIients. Ptienls with an ejeclion fro&n ~35% had rhe 
lowest survivoi ime (76% a~ 3 yeara vs. 97% io padents with 
a modmkly reduced eject& lrsction 05% ;o 49%) and 
96% in patient* with a wmnl ejection fraction (>45%1. 
Cumulative survival w stmngly~associMed with -&dual 
r&ial frsetion lp < o.mw. 
Rolouoaafblfbrct~losor++lThuewre3O7pa. 
tionls who hod tbaO*m-201 inforcl size moosered 8.1 f 64 
weeks oller enrollment. Tlae pstimrs were strotilicd with- 
wise Cox muhiwioto regression o&sir ind&kd that 
oolv the foliowino chmcterisdcs were ass&ted with 
improved so&& high ojcclion fraction (p < 0.001~. 
yooagr age @ = O.WS) ood obseace of history of prior 
myocordiel iofenxioo @ - O.oZ). Aitboogb iofamt sia wes o 
univariak predictor (p - O.L?~). it was net a predictor in the 
timl model. 
lwMo&lpvahe 
Rwa&&&~. Tohle3 shows the numberofcorooary 
performed in the 1st year ol enrollment and in the total 
foilowun &od. Curonarv artery bvrass aatli~n was wr- 
formed io !2l.S% of pat&s in Ihe s&eptokinsse&wp~nd 
17.1% of control oatienls IO = NS): the maiotitv of DDX- 
dares were perfokd during yeki. Con&y &~plasty 
was performed in a small number of patients: 6.8% of 
patients in the streptokinase group and 2.7% of patients in 
the control group in the 1st year and 6.6% of rtreptokinase- 
treated patients and 3.4% of control patients over tk total 
follow-up period. The Western Wsrhin.qtm lrials recom- 
mended hot did not require portthmmbolysis coronary arte 
riography and the decision for revascukizatioo was deter- 
mined by the patient’s own physicim. In comparisoo with 
cwwm prrui-:rhimuup~~.;u(lcor~r~pocul~ 
km 08% in the streptokbnse group and 23% in the convey 
tionally bated gmup). retleets wional medial pmctice at 
the time of patim enmlbomt betweeo 1961 nod 1986. 
Dlsfumlon 
Our readts show that in 616 patients, treammt of acute 
myocardii i&r&m with inhromnsry or inhPvcnoua 
streptokinase si,+cantly lowered the emiy maiality rale, 
but despite a trend for higher survival at a minimum of3 and 
a mean of 4.9 t 2.3 yean after snr,Umcnt. there was no 
rigtdlicaot rttrtoined survival benefit for patients who re. 
ceived streptokinase. Highs eje&ut fractiwl. younger age 
and absence of prior myocardial iofarc&on were the best 
predictors d improved loog-kmt sunrival. 
capsrisea &II tk N&vkmk lnkrntti~ smdy. 
There re:ulk dii% from those in the only other large size. 
raodomi~ed, cootmlkd iowacoronary attd iottwenour svep 
tokiaase trial with a companbk lotg.tenn follow-up period 
(9.19). Between May 1981 sod March 196.5 Ihe Netherlattds 
Iotonmlvcrsiw study enrolled 531 Da&do wb wets tntt. 
tbmized to t&ipi of i-&y sh-eplokioase or to 
a nancathueTized Rmtml gmttp. In January 1984 the 9roro. 
co1 was allered so tbst 76 ptieots received iolravenoos 
s(reptokinw folloursd by intrscomnsty streptokinsse and 
46 also ottderwetd immediate aoaioplssty of the infarct- 
Elated altery. These Ivm subsets of more qgrcssively 
treated patients had the hiiest I-year so&al raks d92% 
aad 96%. respectively, as compxed with a I-year .wrvival 
rate of 88% in 112 patients txeivitt6 only intrawroosry 
sttEptOkiinr#. 
Possibk explanslionr for the ditkrettce between WI 
rest&s sod the Netberlsods stiy ioclude shorter followup 
in a smallor number of ptirntr and earlier tbmmbolytic 
@eatmeat in the Netherlands tial. For exam& at 4 years 
the Weslat Washio6un trials had followed up 391 pdieots 
as compared wilh 292 in the Nelkrlaods study. lo ad&m. 
patients in tbe Netherlands study were ttuted earlier in the 
ccuse d iofarction: patients with a symptom duratlott of 
>4hwereexclodedawJtbemediaorimetokeatmmtwas 
195 mln. In Ihe We&o Wasbiogton triels. combined for this 
emdysis in a manna similar IO the Netherlands trial. patiena 
t8ceiv@lmmwrooary¶mptolriRareweremrereduph7 
12 h after the 011tx.t of rympoms and lhosc rcaiviog 
ottset of sywtorzs. Thor. 9atiutt.s in the-Netherlands trial 
were treated earlii attd rnore aggessively and were fol. 
I~ttpIorashatertiftEpaiOd. 
In Ihe Nethwlands siody. the estimated S-yew sowiwd 
rate -MS 81% fof veftod p&cots and 71% tbr smlml 
ilaknts, IJut Si~aocC *vels were no! repofled. I” our 
sMy al a tttemt f&wttp time d 4.9 yearr, m fumd a 
similar survival rate of&l% in treated pe6eots. but a higha 
Fete dmd of determining pointwise standard emxs. there 
is no Gpnificant difference in 5.ywr survival RIG between 
the awpr or trcutcd palients f-9 = 0.64) DI between the 
control arwtx IP = 0.361 in the tw studies (20). BY the same 
methad. there is no si&iennt ditference in thi &served 
J.year survival dillnetxer between waled patients and 
cuntml wtients ID = 0.40). 
I-year wvival rate was better in the streptokinwre than in 
tk cootti group in both triak (89% vs. 76% in the Xnhcr- 
lsndr study and 83% vs. 72%. in our study). The survivttl rate 
at 5 ycats was much hishcrfor~trcptokinas~t~:~ patieots 
in the Netherlands trial (81%) than in our study (~86). 
uherezr :he survival tate of the wmtml9z&tttr was similar 
l64% vs. 62~). For paticolr with inferior infarction the 
wvival pattern was dhTerent. In the Netherlands study the 
rtovivd t-ate was hi&r for swqaokimswemd by for 
cootrol patienis (91% vs. tB% aI I year and 82% vs. 76@ BI 
5 years). In the Western Washington trials, both strcptoki- 
nas~trc~lled and control pstients with ittfeti infarction had 
excellent long-tetm oowiwd mes: 94% vs. 94% at I year nd 
68% vs. 85% at 5 yearr. Because neither of these n&es we& 
large. tk confidence iotervalr MI these estimales arc quik 
oi.;. ,G assessed by rhe per0 method of determiain9 
standard crrorr, the diaet’eoccs ht survival belweea the Lwo 
studies for patients with anterior aad inferior infarction are 
noi sianilicant P 5 years lp = 0.34 attd o = 0.72. rcsoectivc- 
Iy1. 
Cemowisan with atk shtdks. A similar :tend of im- 
proved&vival to pstieots recciviog uttase was 
teponcd in Ciroppo lmliatto 9er lo Srotlll della Sh-epmchi- 
oasi Nell‘infuto Miowdico (GISSI-11 but wilb followtp 
ottly for I year (41. However, this impmvemeot at 1 parwas 
due to fewer iohosoital de?thr lhat is. wflm malti was 
rkrc was no dSrace between treaimmt gmop at I 
Lower term followop is awaited fmn Ihis tial. The 
APSAC Iolmwatioo MorIality Sotly (AIMS) IZI) has also 
rcpofted I-yearsorvivalralwofET9%t%r~reetcd aodSZ%for 
motml patieoto. lo the Western Wasblnatoo trial the Iso- 
lute difference in mwtality between rtqtokiwotwxted 
andconaolpstieotsw~~~~ysMd5~~lyear.For 
GISSI-I it was 2.3% at 21 days md 1.8% al I year. fm AIMS 
it was 6% al 30 davs sod 7% at I war and for the 
Netherlands ttial it was S.ti% a( 38 days-4 6% at I year 
lSS,9.L9,2ll. Thu. four saodomlld cotttroUed ttizda have 
demotutrated that tbe majority of benefit of thmrmbolpic 
thaqy ~ecun in the 1st momb ami relatively little loar or 
@io in benefit occw over Abe nexi II otooths. Our study 
e~kads Htese obrervatioas IO 5 years. 
Iaaaobswalioaalsmdy.bweyelal.~8)regotted 
Cyear survival rates io 227 patients who received iotmcor- 
ottmy rqtokinase or inttaveoour on?Xnax dS h aftw the 
pby witbin I h of statibtg thmmbolytic thnapy. Patients 
were classi6ed into those with complete repelfusion of the 
infarct-related artery and those with only panial or no 
rctrxfusion. Survival ct 4 years wcs significantly higher in 
tbc arcup with c patent crtery (84% vs. 63% in the pcrticl 
or cc rcprfusion group). Because immediate cormwry srtc- 
riography was not required in the Western Wasbinatoa 
intravenous streptokinase triil, we do not have cnmplete 
data on the early patency ofthc infarct-related ertcry and its 
rctattcn to tong-term survival. However. chc 83% Cycar 
survival rctc in this trial is similnr to the ?A% scrvivcl ntc in 
the ~rwp with a pctect icferct vessel in the study of Mathey 
et al. (8). 
Bareline &teal characterl&s, ej&at fraction aad in- 
farct skc. We found that several admission clinical charac- 
useful in predicting longterm SurviveI, wiircas G&t of 
strcptokiwse wcs not. The ability of clinical cbarcotcristtcs 
to predict early survival bss been reported in Phase II of the 
TIM1 trial (13). However, there was no contml group in that 
trial and it is not wssible to determine whether lhmmbolytic 
agmtc modified &nical risk chamctcristics. We found that 
bcth ejection fraction cad itiarct size were strong oatvariatc 
prcdi&rs of survival. The value of each of these radioaa- 
elide mecswemccts in risk rtretificcdoc cfter infcretion hen 
been pRvioasly established in pelients not receiving thmm- 
bolytic therw (10.11). Despite the hishcomlation between 
ej&tion fra&n and infarci size, ejection fraction was the 
better oredictor of survival in our oatiems 02). la a subset of 
289 patients who had cll has&c entry chcrcctnistics, 
cjccticn frectian and infarct size data. muttivcriatc ccclyaia 
bdicctcd that cjcction fraction wcs the first vartcble to cntcr 
the model and that pgtient age and history of prior myoear- 
dial infarction wwe the only other predictors of survival. 
This observation is in dis&$reenent with iesolts of a pre- 
thrombolytic era stody 0 I) that found infarct size a btitcr 
predictor of adrvivat Lhcn ejection fraction. However, 
follow-up in thct study wcs limited to I year and the 
rcdioncclide studier were obtciacd early bcforc hospital 
discharge. and may not reflect the hue sbdc of lefl ventricular 
tiuction (23). Our nsolts with regard to these variables arc 
limited by the failure to obtain radionoclide data oa all 
patients cnmlkd. 
Ccadcstccs. Follow-up in Ihe Western Wasbioglon 
Strcptckincce in Myocardiat lcfcrction trials demcnstratcs 
that use of intracomrwy or intravenous thrombalytic thcr. 
spy with streptokinase improves early survival, bat does act 
sigdficsotly bapmve survival at 3 to 5 years. Nonsigoiticaat 
treads indicate possible tolls_term benefits for gients with 
yltcrior infer&n. end it IS possible thct lcrgcr patient 
numbers in this group would have dcmcmstrctcd a signbkcat 
benefit. Ejection t&don cad infarct size cre related to 
survival and efforts to decrease infarct size cad incrcasc 
cjcctian fraction may have a beneficial effeot oa loog-term 
survival. To improve survival at 3 to 5 years. elforts aced to 
be dircctcd toward earlier tbrombolytic trcatmmt with more 
c&live egcatr (241. A program for the systematic dctcction 
in those patients with large amoants of myocardiom in 
jeoprdy may improve ventricu!nr fuactton. reduce the like 
tihccd cf reinfcrcdcn and thcrcby improve long-term sur- 
vival (7). 

